|
|
News Breaks
|
February 7, 2012
|
| 08:37 EDT |  | CORT |
| theflyonthewall.com: | Corcept Therapeutics Korlym has good chance to be approved, says Stifel Nicolaus | | After conducting checks, Stifel Nicolaus believes that Corcept's Korlym treatment for Cushing's syndrome is more likely than not to be approved on its February 17 PDUFA date. The firm expects the stock to have strong momentum if Corcept is approved on February 17, and the firm reiterates a Buy rating on the stock. :theflyonthewall.com |
|
|
News For CORT From The Last 14 Days Check below for free stories on CORT the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 17:22 EDT |  | CORT |
|
|
|
|
|
Subscribe for More Information